Download PDF
Endoscopy 2009; 41(7): 575-580
DOI: 10.1055/s-0029-1214826
Original article

© Georg Thieme Verlag KG Stuttgart · New York

Intragastric balloon for weight loss: results in 100 individuals followed for at least 2.5 years

S.  Negrin Dastis1 , E.  François2 , J.  Deviere2 , A.  Hittelet2 , A.  Ilah Mehdi2 , M.  Barea2 , J.  -M. Dumonceau1
  • 1Gastroenterology and Hepatology Service, Geneva University Hospitals, Geneva, Switzerland.
  • 2Medical-Surgical department of gastroenterology, hepatopancreatology and Digestive oncology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium
Further Information

Publication History

submitted12 October 2008

accepted after revision26 March 2009

Publication Date:
08 July 2009 (online)

Also available at
    Permissions and Reprints

See also:

Commentaire de travail de S. Negrin Dastis et al., pp. 575Endoscopy 2009; 41(07): 737-737
DOI: 10.1055/s-0032-1306736

Background and study aims: To determine long-term outcome after treatment with an intragastric balloon for 6 months, with no structured weight maintenance program offered after balloon removal.

Patients and methods: 100 consecutive overweight/obese individuals (mean body mass index [BMI] 35.0 ± 5.6 kg/m2) were prospectively followed after endoscopic implantation of a saline-filled intragastric balloon; 97 completed final follow-up at a mean of 4.8 ± 1.6 years. Successful intragastric balloon therapy was defined as weight loss at 6 months of ≥ 10 % of weight at baseline, that remained ≥ 10 % until 2.5 years, without bariatric surgery. All analyses followed intention-to-treat principles.

Results: At 6 months, mean weight loss was 12.6 ± 8.3 kg, 63 individuals had ≥ 10 % baseline weight loss; no severe morbidity was detected. During the first and second years following intragastric balloon removal, mean body mass increased by 4.2 ± 6.8 and 2.3 ± 6.0 kg, respectively (P < 0.001 for both year-on-year comparisons). At 2.5 years, intragastric balloon therapy had been successful in 24 participants. At final follow-up (4.8 ± 1.6 years), 28 had ≥ 10 % baseline weight loss, 35 had undergone bariatric surgery (60 % had preoperative mass higher than baseline), and 3 were lost to follow-up; the 34 remaining had lost 1.5 ± 5.8 kg compared with baseline. During follow-up, 13 had a second intragastric balloon implanted and 13 took sibutramine for short periods.

Conclusion: Intragastric balloon therapy was relatively innocuous and associated with successful weight loss and maintenance at 2.5 years in a quarter of participants. It represents a valid option for weight loss.

References

  • 1 World Health Organization .Obesity: Preventing and managing the global epidemic. WHO Obesity Technical Report Series 894; World Health Organization, Geneva, Switzerland. 2000
    Google Scholar
  • 2 Anonymous . Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. The evidence report. National Institutes of Health.  Obes Res. 1998;  6 (Suppl 2) 51S-209S
    PubMedGoogle Scholar
  • 3 Schapiro M, Benjamin S, Blackburn G. et al . Obesity and the gastric balloon: a comprehensive workshop. Tarpon Springs, Florida, March 19–21 1987.  Gastrointest Endosc. 1987;  33 323-327
    CrossrefPubMedGoogle Scholar
  • 4 Genco A, Cipriano M, Bacci V. et al . BioEnterics intragastric balloon (BIB): a short-term, double-blind, randomised, controlled, crossover study on weight reduction in morbidly obese patients.  Int J Obes. 2006;  30 129-133
    CrossrefPubMedGoogle Scholar
  • 5 Martinez-Brocca M A, Belda O, Parejo J. et al . Intragastric balloon-induced satiety is not mediated by modification in fasting or postprandial plasma ghrelin levels in morbid obesity.  Obes Surg. 2007;  17 649-657
    CrossrefPubMedGoogle Scholar
  • 6 Mathus-Vliegen E M, Tytgat G N. Intragastric balloon for treatment-resistant obesity: safety, tolerance, and efficacy of 1-year balloon treatment followed by a 1-year balloon-free follow-up.  Gastrointest Endosc. 2005;  61 19-27
    CrossrefPubMedGoogle Scholar
  • 7 Zago S, Kornmuller A M, Agagliati D. et al . [Benefit from bio-enteric Intra-gastric balloon (BIB) to modify lifestyle and eating habits in severely obese patients eligible for bariatric surgery].  Minerva Medica. 2006;  97 51-64
    PubMedGoogle Scholar
  • 8 Sallet J A, Marchesini J B, Paiva D S. et al . Brazilian multicenter study of the intragastric balloon.  Obes Surg. 2004;  14 991-998
    CrossrefPubMedGoogle Scholar
  • 9 Heshka S, Anderson J W, Atkinson R L. et al . Weight loss with self-help compared with a structured commercial program: a randomized trial.  JAMA. 2003;  289 1792-1798
    CrossrefPubMedGoogle Scholar
  • 10 Dumonceau J M. Evidence-based review of the Bioenterics intragastric balloon for weight loss.  Obes Surg. 2008;  18 1611-1617
    CrossrefPubMedGoogle Scholar
  • 11 Lorentz F H. Der konstitutionsindex der frau.  Klin Wochenshr. 1929;  16 734-736
    PubMedGoogle Scholar
  • 12 Cotton P B. Outcomes of endoscopy procedures: struggling towards definitions.  Gastrointest Endosc. 1994;  40 514-518
    CrossrefPubMedGoogle Scholar
  • 13 Apfelbaum M, Vague P, Ziegler O. et al . Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine.  Am J Med. 1999;  106 179-184
    CrossrefPubMedGoogle Scholar
  • 14 Wadden T A, Berkowitz R I, Womble L G. et al . Randomized trial of lifestyle modification and pharmacotherapy for obesity.  N Engl J Med. 2005;  353 2111-2120
    Google Scholar
  • 15 Wirth A, Krause J. Long-term weight loss with sibutramine: a randomized controlled trial.  JAMA. 2001;  286 1331-1339
    CrossrefPubMedGoogle Scholar
  • 16 James W P, Astrup A, Finer N. et al . Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine trial of obesity reduction and maintenance.  Lancet. 2000;  356 2119-2125
    CrossrefPubMedGoogle Scholar
  • 17 Herve J, Wahlen C H, Schaeken A. et al . What becomes of patients one year after the intragastric balloon has been removed?.  Obes Surg. 2005;  15 864-870
    CrossrefPubMedGoogle Scholar
  • 18 Doldi S B, Micheletto G, Perrini M N, Rapetti R. Intragastric balloon: another option for treatment of obesity and morbid obesity.  Hepato-Gastroenterology. 2004;  51 294-297
    PubMedGoogle Scholar
  • 19 Genco A, Bruni T, Doldi S B. et al . BioEnterics intragastric balloon: The Italian experience with 2,515 patients.  Obes Surg. 2005;  15 1161-1164
    CrossrefPubMedGoogle Scholar
  • 20 Dansinger M L, Tatsioni A, Wong J B. et al . Meta-analysis: the effect of dietary counseling for weight loss.  Ann Intern Med. 2007;  147 41-50
    CrossrefPubMedGoogle Scholar
  • 21 Svetkey L P, Stevens V J, Brantley P J. et al . Comparison of strategies for sustaining weight loss: the weight loss maintenance randomized controlled trial.  JAMA. 2008;  299 1139-1148
    CrossrefPubMedGoogle Scholar
  • 22 Wing R R, Tate D F, Gorin A A. et al . A self-regulation program for maintenance of weight loss.  N Engl J Med. 2006;  355 1563-1571
    CrossrefPubMedGoogle Scholar
  • 23 Eddy D M, Schlessinger L, Kahn R. Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes.  Ann Intern Med. 2005;  143 251-264
    CrossrefPubMedGoogle Scholar
  • 24 Melissas J, Mouzas J, Filis D. et al . The intragastric balloon – smoothing the path to bariatric surgery.  Obes Surg. 2006;  16 897-902
    CrossrefPubMedGoogle Scholar
  • 25 Flum D R, Khan T V, Dellinger E P. Toward the rational and equitable use of bariatric surgery.  JAMA. 2007;  298 1442-1444
    CrossrefPubMedGoogle Scholar
  • 26 Wadden T A, Butryn M L, Wilson C. Lifestyle modification for the management of obesity.  Gastroenterology. 2007;  132 2226-2238
    Google Scholar
  • 27 Puglisi F, Antonucci N, Capuano P. et al . Intragastric balloon and binge eating.  Obes Surg. 2007;  17 504-509
    CrossrefPubMedGoogle Scholar
  • 28 Machytka E, Klvana P, Hanuskova L, Janik I. Use of pharmacotherapy for long-term maintenance of weight loss following explantation of intragastric balloon (BIB).  Gut. 2007;  57 A290
    PubMedGoogle Scholar
  • 29 Padwal R, Kezouh A, Levine M, Etminan M. Long-term persistence with orlistat and sibutramine in a population-based cohort.  Int J Obes. 2007;  31 1567-1570
    CrossrefPubMedGoogle Scholar
  • 30 Rucker D, Padwal R, Li S K. et al . Long term pharmacotherapy for obesity and overweight: updated meta-analysis.  BMJ. 2007;  335 1194-1199
    CrossrefPubMedGoogle Scholar
  • 31 Cotton P B. Randomization is not the (only) answer: a plea for structured objective evaluation of endoscopic therapy.  Endoscopy. 2000;  32 402-405
    Article in Thieme ConnectPubMedGoogle Scholar
  • 32 Dhruva S S, Redberg R F. Variations between clinical trial participants and Medicare beneficiaries in evidence used for Medicare national coverage decisions.  Arch Intern Med. 2008;  168 136-140
    CrossrefPubMedGoogle Scholar
  • 33 Weiss N S, Koepsell T D, Psaty B M. Generalizability of the results of randomized trials.  Arch Intern Med. 2008;  168 133-135
    CrossrefPubMedGoogle Scholar

J.-M. DumonceauMD, PhD 

Division of Gastroenterology and Hepatology
Geneva University Hospitals

Rue Micheli-du-Crest 24
1205 Geneva
Switzerland

Fax: +41-22-3729366

Email: jmdumonceau@hotmail.com

      >